Ra Capital Management LLC is a principal investment firm that invests in public and private healthcare and life science companies. The firm’s mainly focuses on prevention and cures, investing in companies that develop drugs, healthcare devices and interventions. Ra Capital Management LLC recently submitted its SEC 13F filings for the period ended September 30, 2014, showing that Dyax Corp. (NASDAQ:DYAX), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were its top three holdings for the quarter.
The primary investment of Ra Capital Management LLC for the quarter was Dyax Corp. (NASDAQ:DYAX), with a total of $79.03 million. Dyax Corp. (NASDAQ:DYAX) is a biopharmaceutical company that focuses on the discovery, development and sale of medical substances such as antibiotics, small proteins, and peptides. Ra Capital Management had the highest number of shares of the company with a total of 7.81 million shares. Baker Bros. Advisors came in second with a total of 6.16 million. (You can see complete list on hedge funds which hold positions on Dyax Corp. (NASDAQ:DYAX) at the end of the third quarter).
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the second largest investment of the firm with a total of $69.14 million. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a pharmaceutical company that focuses its activities on the design and development of small-molecule novel medicines that help block specific enzymes that are involved in causing infectious diseases, inflammation, and cancer. In the company’s latest quarterly report, it posted $0.12 in earnings per share on revenue of $3.20 million. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was recently given an “overweight” rating by JPMorgan Chase & Co. and a price target of $20.00.
The third largest investment of Ra Capital Management LLC was Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), accounting for a total of $66.87 million in value. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a pharmaceutical company that discovers, designs, and develops medical solutions for infectious diseases that include hepatitis, HIV, and resistant bacterial infections. The company is currently developing a hepatitis C drug, which is to be used alongside Sovaldi drug produced by Gilead Sciences. The success of the second Phase experiments has made the stock a darling of many investors. The performance of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for the third quarter 2014 was wanting, reporting a net loss of $15.7 million, translating into $0.16 per share.
This article has been written by Victor Ochieng.